Humana (NYSE:HUM) Releases Quarterly Earnings Results

Humana (NYSE:HUM) released its earnings results on Tuesday. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10, Zacks reports. Humana had a return on equity of 13.20% and a net margin of 1.18%. Humana updated its FY 2025 guidance to 16.250-16.250 EPS.

Humana Price Performance

Shares of NYSE:HUM opened at $256.69 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The business’s fifty day moving average price is $273.00 and its two-hundred day moving average price is $295.72. The stock has a market cap of $30.91 billion, a PE ratio of 22.74, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. Humana has a one year low of $213.31 and a one year high of $406.46.

Wall Street Analyst Weigh In

HUM has been the subject of a number of analyst reports. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and upped their price objective for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Barclays increased their price target on shares of Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 22nd. Morgan Stanley lowered their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday. Truist Financial increased their target price on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Finally, Piper Sandler lifted their price target on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Nineteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $296.84.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.